Purpose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant pleural mesothelioma (MPM).
INTRODUCTION
Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer usually caused by asbestos exposure. 1 The incidence of MPM is expected to have peaked, or to peak in the coming years in countries that have carefully regulated the commercial use of asbestos.
2 However, asbestos remains in use in many regions, which are likely to see a corresponding increase in cases of MPM. 3, 4 MPM is typically diagnosed at an advanced stage and overall prognosis is poor, with median overall survival (OS) reported to be as short as 7 months. 1 For patients with unresectable disease, systemic first-line treatment with pemetrexed and cisplatin is the standard of care, 5, 6 on the basis of a phase III study that reported an increase of 2.8 months in OS compared with cisplatin alone (12.1 v 9.3 months). 7 There are currently no approved agents for second-line treatment, although pemetrexed-based regimens (if not used as first-line therapy), vinorelbine, gemcitabine, or enrollment in a clinical trial are recommended by some guidelines. 5, 6 Studies with the multitargeted small-molecule tyrosine kinase inhibitors cediranib, dasatinib, sorafenib, and sunitinib have failed to show adequate clinical activity as second-line treatments when used as monotherapy. [8] [9] [10] [11] There is a clear need for more effective treatments. Although several clinical trials have evaluated novel compounds in combination with pemetrexed and cisplatin as first-line treatment, so far there have been few advances.
In an open-label, phase III study (Mesothelioma Avastin Cisplatin Pemetrexed Study [MAPS] ), the addition of bevacizumab to pemetrexed and cisplatin (with maintenance bevacizumab) significantly increased OS (median OS, 18.8 v 16.1 months; hazard ratio [HR] , 0.77; P = .017). 5 Data from the MAPS study 5 support the concept that inhibition of signaling by the vascular endothelial growth factor (VEGF) pathway may be a potential treatment option for MPM. 12 Nintedanib is an oral, twice-daily, angiokinase inhibitor targeting VEGF receptors 1, 2, and3, platelet-derived growth factor receptors a/b, fibroblast growth factor (FGF) receptors 1, 2, and 3, as well as Src and Abl kinase signaling. 13, 14 At the time this study was designed, VEGF signaling was known to play an important role in mesothelioma pathophysiology. [15] [16] [17] [18] Other signaling pathways inhibited by nintedanib had also been proposed as valid therapeutic targets, including the Src and Abl kinases, which are involved in MPM cell migration, 19, 20 and FGF, which is overexpressed in MPM tumor samples. 21 Targeting more than one pathway may have the potential for increased efficacy, and this provided the rationale for investigating nintedanib in MPM. Unlike previously investigated small-molecule tyrosine kinase inhibitors, nintedanib has a manageable safety profile in combination with commonly used chemotherapy agents, making it suitable to be investigated in combination with standard-of-care firstline cisplatin plus pemetrexed.
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Here we report the results of the phase II part of LUME-Meso (ClinicalTrials.gov identifier: NCT01907100), an ongoing phase II/ III study designed to evaluate the safety and efficacy of standard chemotherapy combined with nintedanib or placebo in the firstline treatment of patients with unresectable MPM (clinical trial identifier: NCT01907100).
PATIENTS AND METHODS

Study Design and Patients
The LUME-Meso study was initially designed as a phase II, doubleblind, randomized trial of nintedanib or placebo in combination with Randomly assigned to placebo plus pemetrexed and cisplatin (ITT population; n = 43) standard treatment of pemetrexed and cisplatin, followed by continuing nintedanib or placebo monotherapy as first-line treatment of patients with unresectable nonsarcomatoid MPM. The phase II part of the study was conducted at 18 sites in eight countries (Appendix Table A1 , online only).
Eligible patients were $ 18 years of age, with histologically confirmed, unresectable epithelioid or biphasic MPM (Eastern Cooperative Oncology Group performance status 0 or 1) and measurable disease according to Response Evaluation Criteria In Solid Tumors modified for mesothelioma (mRECIST). 27 Key exclusion criteria were previous systemic chemotherapy for MPM and sarcomatoid MPM (Appendix, online only).
Health authorities and independent ethics committees or institutional review boards at each country/center approved the protocol on the basis of local regulations. The study was conducted in accordance with good clinical practice and followed the guiding principles of the Declaration of Helsinki, as well as local laws and regulations. All patients provided written informed consent.
Randomization, Patient Allocation, and Procedures
Patients were randomly assigned in a 1:1 ratio to receive nintedanib or placebo. Randomization was stratified by histology (epithelioid or biphasic).
Treatment with pemetrexed and cisplatin and either nintedanib or matching placebo was given in 21-day courses. Pemetrexed and cisplatin were administered for a maximum of six cycles at the following standard dosages: 500 mg/m 2 intravenous (IV) over 10 minutes on day 1 of each 21-day cycle for pemetrexed, and 75 mg/m 2 IV over 2 hours on day 1 of each 21-day cycle for cisplatin. Nintedanib was given orally at 200 mg twice daily on days 2 through 21 of each 21-day cycle. Patients who did not experience progression during the combination therapy phase continued to receive nintedanib or placebo monotherapy until disease progression, undue toxicity, and withdrawal of consent or death. Predefined dose reduction was allowed to manage adverse events (AEs).
Tumor-response assessment by computed tomography was performed at baseline (within 4 weeks before first treatment) and then every 6 weeks (6 1 week) and continued until progression or discontinuation from study. Tumor response was evaluated using mRECIST 27 according to investigator assessment.
Safety was assessed regularly according to the protocol using US National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. AEs of interest were categorized using standardized Medical Dictionary for Regulatory Activities-queries tailored to special search categories.
End Points
The primary end point was progression-free survival (PFS) by investigator assessment, defined as the time from random assignment to the date of disease progression according to mRECIST, 27 or death from any cause. OS and objective response were secondary end points.
Statistical Analysis
For the phase II portion of the study, the sample size was calculated to provide an initial assessment of the safety and efficacy of adding nintedanib to pemetrexed and cisplatin, and was based on an assumed HR for PFS of 0.75 (median PFS, 8 months for the nintedanib plus pemetrexed and cisplatin combination v 6 months for the placebo-pemetrexed-cisplatin regimen). Originally, the primary analysis of PFS was planned after 65 PFS events (approximately 75% of all randomly assigned patients). The target sample size was, therefore, 86 patients. This was considered sufficient to have a high probability of detecting a true signal of treatment benefit.
Following the data monitoring committee recommendation to modify the trial into a confirmatory phase III study, and after consultation with regulatory authorities, the phase II part of the trial was unblinded for the primary PFS analysis to refine assumptions for sample size calculation in phase III (data cutoff, March 4, 2016) . The number of phase II PFS events (ie, progression and deaths) reached at that time was 69. The primary OS analysis and corresponding updated PFS analysis was to be performed after approximately 61 deaths.
Efficacy analyses included all randomly assigned patients, using the intention-to-treat principle. PFS and OS were analyzed using KaplanMeier methods. P values were calculated from the two-sided stratified logrank test. The objective response rate was compared between treatment groups using a logistic regression model. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC) and are intended to be descriptive.
The phase III part started recruitment in May 2016, remains blinded, and will be used for the confirmatory analysis of this trial. The patients included in phase II will not be counted toward phase III recruitment.
RESULTS
Patients
Between September 2013 and December 2014, 104 patients were screened and 87 patients were randomly assigned to treatment with pemetrexed and cisplatin and either nintedanib (n = 44) or matching placebo (n = 43). Two patients in the placebo arm jco.org never received any study treatment because of contraindications. Details of patient disposition are shown in Figure 1 . Clinical characteristics and demographics in each arm showed similar baseline parameters (Table 1 ). Overall, the median age of patients was 67 years, 79% of patients were male, 89% had epithelioid histology, and 70% had known previous exposure to asbestos. Five (11.4%) patients in the nintedanib group and two (4.7%) patients in the placebo group had previous surgery.
Median duration of nintedanib/placebo treatment was 7.8 months (range, 0.1 to 33.2 months) in the nintedanib group and 5.3 months (range, 0.4 to 28.9 months) in the placebo group at the time of the primary OS analysis. Median follow-up was 29.0 months (95% CI, 26.9 to 33.1 months).
The median number of pemetrexed and cisplatin courses was six in both treatment groups. In the nintedanib arm, 26 patients (59.1%) received six cycles of pemetrexed and 23 patients (52.3%) received six cycles of cisplatin. In the placebo arm, 22 patients (53.7%) received six cycles of pemetrexed and 21 patients (51.2%) received six cycles of cisplatin. Pemetrexed dose reductions were observed in 11 patients (25.0%) treated with nintedanib and two (4.9%) in the placebo arm, whereas cisplatin dose reductions were observed in nine patients (20.5%) treated with nintedanib and five (12.2%) in the placebo arm.
Nintedanib dose reductions were required in 17 patients (38.6%), of whom five patients (11.4%) required a second dose reduction. Placebo dose reduction was required in seven patients (17.1%). Mean dose intensities for chemotherapy and for nintedanib and placebo are listed in Table 2 .
Efficacy
The main efficacy results for the overall population as well as the population analyzed by histology are listed in Table 3 . Nintedanib treatment improved PFS compared with placebo. This finding was observed at the primary PFS analysis with 69 PFS events (HR, 0.56; 95% CI, 0.34 to 0.91; P = .017) and confirmed at the updated analysis (HR, 0.54; 95% CI, 0.33 to 0.87; P = .010) with 72 PFS events.
When analyzed by histology, improvement in PFS was evident in patients with epithelioid histology (HR, 0.49; 95% CI, 0.30 to 0.82; P = .006). The number of patients with biphasic histology MPM (n = 10) was too low to provide a reliable estimate of the treatment effect. Kaplan-Meier curves of PFS for the overall patient population and the epithelioid population at the time of the primary OS analysis are shown in Figures 2A and 2B ; treatment with nintedanib improved median PFS by 3.7 months for the overall population and by 4.0 months for the epithelioid population.
At the time of the primary OS analysis, 62 OS events (71%) had occurred. Analysis of OS showed an improvement favoring nintedanib treatment in all patients (median OS, 18.3 months in nintedanib group v 14.2 months in placebo group; HR, 0.77; 95% CI, 0.46 to 1.29; P = .319; Table 3 and Fig 2C) . For patients with epithelioid histology the median OS was 20.6 months with nintedanib v 15.2 months with placebo (HR, 0.70; 95% CI, 0.40 to 1.21; P = .197; Table 3 and Fig 2D) .
The effect of nintedanib on PFS and OS was consistent across the subgroups, with the exception of patients with biphasic histology (Fig 3) .More than half of patients in each treatment group (nintedanib 64% v placebo 70%) received subsequent therapy (Appendix Table A2 , online only). The best overall tumor response according to mRECIST criteria showed more objective responses (all partial responses) in the nintedanib arm (n = 25; 56.8%) than in the placebo arm (n = 19; 44.2%; odds ratio, 1.66; 95% CI, 0.72 to 3.9).
Safety and Adverse Events
All patients experienced at least one AE of any grade and nearly all patients in the nintedanib (97.7%) and placebo (97.6%) groups experienced an investigator-defined drug-related AE. The most frequently reported AEs ($ 60% of patients, any CTCAE grade) in the nintedanib arm and more frequent with nintedanib than placebo were diarrhea and neutropenia. Table 4 lists the most common AEs by group terms. Grade $ 3 AEs were reported in 35 patients (79.5%) in the nintedanib arm and 22 patients (53.7%) in the placebo arm. There was an increased frequency of grade $ 3 group-term AEs of neutropenia in the nintedanib arm (43.2% v 12.2%), although the rate of febrile neutropenia (group term) was low (4.5%; n = 2) in the nintedanib arm and not reported with placebo. There were no reports of sepsis with nintedanib.
Incidence of AEs (group terms) commonly associated with anti-angiogenic agents were either balanced between treatment arms or reported in lower numbers of patients in the nintedanib arm. The events of interest (nintedanib v placebo) included bleeding (11.4% v 12.2%), GI perforation (0% v 2.4%), thromboembolism (9.1% v 17.1%), and venous thromboembolism (6.8% v 14.6%). There were no reports of arterial thromboembolism.
Serious AEs (SAEs) occurred in 18 patients (40.9%) in the nintedanib arm and in 17 patients (41.5%) in the placebo arm. The most frequent SAEs (all grades; nintedanib v placebo) were neutropenia (9.1% [n = 4] v 2.4% [n = 1]), diarrhea (6.8% [n = 3] v 0), pyrexia (6.8% [n = 3] v 4.9% [n = 2]), and pulmonary embolism (2.3% [n = 1] v 9.8% [n = 4], respectively). Three patients in the placebo arm died as a result of SAEs: one patient from disease progression, one patient from general physical health deterioration, and one patient from both disease progression and treatment-related nephrotic syndrome. One fatal SAE was reported in the nintedanib group (disease progression unrelated to treatment). 
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Three patients (6.8%) in the nintedanib arm and seven patients (17.1%) in the placebo arm experienced AEs leading to permanent discontinuation of last study medication. AEs leading to discontinuation in the nintedanib arm included upper abdominal pain and vomiting in one patient; increased aspartate aminotransferase/blood alkaline phosphatase levels in one patient; and neutropenia, aplasia, and Klebsiella pneumonia in one patient; no patients discontinued treatment because of diarrhea. Fourteen patients (31.8%) in the nintedanib arm and six (14.6%) in the placebo arm experienced AEs leading to dose reduction of nintedanib or placebo. AEs leading to dose reduction of nintedanib occurring in more than one patient included diarrhea (9.1%), increased alanine aminotransferase levels (9.1%), nausea (4.5%), and neutropenia (4.5%).
DISCUSSION
The addition of nintedanib to standard pemetrexed and cisplatin therapy demonstrated improved clinical efficacy in the first-line treatment of patients with MPM, as evidenced by improved PFS with a corresponding improvement in OS and a manageable safety profile. A benefit was observed in patients with epithelioid histology; the median PFS prolongation of 4 months in these patients (with minimal additional toxicity) provided the rationale to proceed to the phase III component of the study. The median OS time of 20.6 months achieved in the epithelioid histology subtype is, to our knowledge, the longest reported in a randomized, doubleblind phase II study.
The positive findings of the MAPS study with the addition of bevacizumab to standard pemetrexed plus cisplatin provide context to our data. The HR for PFS was 0.61 (95% CI, 0.50 to 0.75; median 9.2 months with bevacizumab v 7.3 months with placebo) in the MAPS study, whereas the HR for OS was 0.77 (95% CI, 0.62 to 0.95; median 18.2 months with bevacizumab v 16.1 months with placebo). In our trial, with all the limitations related to differences between the studies, the HRs for PFS and OS confirm the value of targeting angiogenesis as a treatment approach in MPM. Interestingly, in the MAPS trial, the effect of bevacizumab on survival was more pronounced in patients with sarcomatoid or mixed histology (HR, 0.64; 95% CI, 0.40 to 1.02) than in patients with epithelioid histology (OS HR, 0.82; 95% CI, 0.64 to 1.06). However, between-trial comparisons should be done with caution because of the differences in size (phase II for LUME-Meso v phase Although inhibition of angiogenesis via VEGF by bevacizumab has been demonstrated as a viable approach, nintedanib combines VEGF receptor inhibition with targeting other pathways: namely, the platelet-derived growth factor pathway, associated with poor prognosis in MPM, 28 and the FGF receptor pathway, implicated in the pathogenesis of MPM in preclinical studies. 12 In addition to the inhibition of proangiogenic signaling, preclinical data show that nintedanib strongly reduces the colony-forming capacity and migratory activity of MPM cell lines-this appears to be a direct effect on the mesothelioma cells themselves 29, 30 -and inhibits MPM tumor growth in human xenograft models. 29 It is possible that Src inhibition by nintedanib 14 may add to the clinical activity in patients with MPM. The broad inhibition profile of nintedanib, coupled with the direct antitumor activity, may account for the promising results observed.
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The overall safety profile of nintedanib in combination with chemotherapy was as expected from previous studies. AEs were manageable. Although the incidence of diarrhea reported here was higher than reported with nintedanib when given with docetaxel in a study of lung cancer, 24 rates are similar to those previously reported when nintedanib was given with a doublet chemotherapy, such as with paclitaxel plus carboplatin or modified infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX6).
23,31 Although diarrhea was common, it was mainly of low grade, reversible with dose interruption, and no patients permanently discontinued study medication because of this event. Clinical experience with nintedanib in non-small cell lung cancer indicates that diarrhea can be managed with appropriate medication or existing dose reduction protocols.
32 Certain grade $ 3 AEs were reported more frequently in the nintedanib arm than in the placebo arm, including increased liver enzyme levels and neutropenia, although complications of the latter, such as febrile neutropenia, were low; sepsis was also not reported. Liver enzyme elevations have been reported previously with nintedanib in combination with docetaxel and are generally reversible and manageable. 24 Incidences of AEs typically associated with VEGF/VEGF-receptor inhibitors were either balanced between the groups, as in the case of hypertension, or reported in fewer patients in the nintedanib arm.
The dose intensity of the pemetrexed plus cisplatin regimen was maintained in the presence of nintedanib. The median number of pemetrexed plus cisplatin courses was six in both groups. Approximately twice as many patients in the nintedanib group, compared with the placebo group, experienced an AE leading to dose reduction of nintedanib or placebo; however, the rate of AEs leading to discontinuation was higher in the placebo group. The proportion of patients who received poststudy treatment was also similar between groups (nintedanib, 64% v placebo, 70%), indicating that addition of nintedanib to standard doublet chemotherapy did not adversely influence patients' ability to receive subsequent treatments.
The strengths of this phase II study include a randomized double-blind design, removing potential sources of bias. Although recent research has suggested that PFS may not be a valid surrogate end point for OS in MPM, 33 analyses were conducted on small, phase II studies, most of which included only one treatment arm and did not include pemetrexed. These factors may have had an effect on the lack of observed correlation between PFS and OS. The trend toward improved OS in our study is reassuring and adds to the evidence from other larger trials that have shown an association. 5, 7 Several limitations should be considered. These include the relatively small sample size requiring confirmation of results, and the small number of patients with biphasic histology, which limited the interpretation of results in this subgroup. Lack of central pathologic review and independent review of disease progression is also a limitation in a trial setting. Finally, no predictive biomarker that could improve patient selection for nintedanib treatment has been identified in patients with MPM. However, blood samples have been collected in phase II and will be collected during phase III to investigate potential biomarkers.
In conclusion, the addition of nintedanib to standard chemotherapy demonstrated a clinically meaningful benefit in the first-line treatment of patients with MPM. The benefit was evident in patients with epithelioid histology. These findings warrant confirmation and the global, prospectively randomized, phase III trial is recruiting patients with epithelioid MPM to confirm the activity of nintedanib in this patient population.
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